Arax Advisory Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arax Advisory Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$883K	Buy	15,439 +12,335	+397%	+$676K	0.01%	1290
2026 Q1	$174K	Buy	3,104 +2,981	+2,424%	+$174K	﹤0.01%	1150
2025 Q4	$7.31K	Sell	123 -103,211	-100%	-$5.62M	﹤0.01%	2646
2025 Q3	$5.6M	Buy	103,334 +103,251	+124,399%	+$5.9M	0.08%	205
2025 Q2	$4.56K	Sell	83 -31	-27%	-$1.82K	﹤0.01%	2287
2025 Q1	$8.06K	Buy	114 +76	+200%	+$5.11K	﹤0.01%	1625
2024 Q4	$2.5K	Buy	38 +26	+217%	+$1.74K	﹤0.01%	1955
2024 Q3	$844	Buy	12 +3	+33%	+$251	﹤0.01%	2308
2024 Q2	$741	Buy	+9	New	+$749	﹤0.01%	2252
2023 Q4	–	Sell	-7	Closed	-$620	–	1345
2023 Q3	$620	Sell	7 -11	-61%	-$979	﹤0.01%	1216
2023 Q2	$1.56K	Sell	18 -1	-5%	-$94	﹤0.01%	1035
2023 Q1	$1.85K	Hold	19	–	–	﹤0.01%	1000
2022 Q4	$1.97K	Hold	19	–	–	﹤0.01%	943
2022 Q3	$2K	Buy	+19	New	+$1.69K	﹤0.01%	939
2022 Q1	–	Sell	-15	Closed	-$1K	–	1154
2021 Q4	$1K	Buy	+15	New	+$1.24K	﹤0.01%	973
2018 Q3	–	Sell	-237	Closed	-$22K	–	630
2018 Q2	$22K	Buy	237 +2	+0.9%	+$175	0.01%	288
2018 Q1	$19K	Buy	+235	New	+$20.2K	0.01%	283
2017 Q3	–	Sell	-19	Closed	-$2K	–	469
2017 Q2	$2K	Hold	19	–	–	﹤0.01%	439
2017 Q1	$1K	Hold	19	–	–	﹤0.01%	480
2016 Q4	$2K	Buy	+19	New	+$1.63K	﹤0.01%	456

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Arax Advisory Partners's BMRN Position: Q2 2026 in Review

Arax Advisory Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 397% in Q2 2026, buying an estimated $676K and bringing the position to 15,439 shares worth $883K. The position accounts for 0.01% of the portfolio, ranked #1290.

Arax Advisory Partners first reported a position in BMRN in Q4 2016 and has held it in 20 quarters since. The position peaked at $5.6M in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Arax Advisory Partners held 15,439 shares of BioMarin Pharmaceuticals worth $883K as of Q2 2026.
Arax Advisory Partners bought 12,335 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $676K.
BioMarin Pharmaceuticals made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1290 holding.
Arax Advisory Partners first reported a position in BioMarin Pharmaceuticals in Q4 2016 and has held it in 20 quarters since.
Arax Advisory Partners's BioMarin Pharmaceuticals position peaked at $5.6M in Q3 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.